Pterostilbene

Pterostilbene at a Glance

Pterostilbene is a stilbene from blueberries and Indian kino tree heartwood, and the close structural relative of resveratrol — two of resveratrol’s hydroxyl groups replaced with methoxy groups.

That small change is the whole reason it exists as a supplement: the methyl groups make it far more lipophilic and much harder for the gut and liver to conjugate away, giving it dramatically better oral bioavailability than resveratrol while acting on the same targets.

What It’s Used For

• Glucose & metabolic regulation — improves glucose handling and metabolic markers.
• Blood pressure — lowers blood pressure.
• Liver / NAFLD markers — improves liver markers in fatty liver disease.
• Cognition & neuroprotection — supports cognition and protects neurons.
• Cancer chemoprevention — studied for cancer chemoprevention.

How It Works

Pterostilbene activates SIRT1 and AMPK, the two sensors that tell a cell it is energy-scarce and should switch from storage to burning — the same pathways resveratrol targets and the basis of the metabolic and longevity interest. It also activates Nrf2, the master switch for antioxidant gene expression, and inhibits NF-κB inflammatory signalling.

The pharmacokinetics are what distinguish it. Resveratrol is conjugated so efficiently in the gut wall and liver that little free compound reaches circulation; pterostilbene’s methoxy groups resist that, giving it several times the oral bioavailability and a considerably longer half-life. It is fat-soluble and taken with food.

The full trial record is in Pharmacology & Research below.

Pharmacology & Research

Pterostilbene is a dimethylated stilbenoid — the 3,5-dimethyl ether of resveratrol — found chiefly in blueberries, and it is sold as a longevity and metabolic-support nootropic. Its two methoxy groups make it markedly more lipophilic and metabolically stable than resveratrol, which is the whole reason it exists as a distinct supplement: it gets absorbed and stays around, where resveratrol largely does not. The catch is that most of what is claimed for it rests on cell and rodent work; the human trial base is small, and several of the best-known human studies actually tested pterostilbene combined with nicotinamide riboside (the “Basis”/NRPT formula), which makes it hard to credit any effect to pterostilbene alone. The one clean human efficacy signal — a modest blood-pressure drop — came alongside an unwanted rise in LDL cholesterol, so the honest read is “promising bioavailability, thin and mixed human outcomes.”

Evidence by IndicationStrength of support · Beta

Support is an experimental score I’m building — a composite weighted by study type (human > animal > in vitro > review) and study volume. It’s a beta: a fast way to rank strength of evidence at a glance, not a validated metric. Each application links down to its write-up.

01Blood pressurePromising55%One RCT (n=80, 250 mg/day); clear −8 mmHg effect but single trial, and offset by an LDL rise.

02Liver / NAFLD markersShaky40%One 6-month RCT (n=111) but pterostilbene was bundled with nicotinamide riboside; primary endpoint null.

03Glucose & metabolic regulationShaky32%Diabetic-rodent and in-vitro AMPK/gluconeogenesis data; only a minor human weight change.

04Cognition & neuroprotectionShaky28%Aged-rat and Alzheimer-model mouse studies; brain penetration is a real mechanistic hook, but no human trial.

05Cancer chemopreventionShaky18%In-vitro across many tumor lines plus a transgenic-mouse prostate model; no human efficacy data.

Mechanisms

Pharmacokinetics

Pharmacokinetics is the decision-relevant part of the pterostilbene story. The two methoxy groups replace hydroxyls that resveratrol loses rapidly to glucuronidation and sulfation, so pterostilbene resists first-pass conjugation and is more lipophilic. In rats given equimolar oral doses, pterostilbene reached far higher and longer-lasting plasma levels than resveratrol ^{7Reference 7Kapetanovic et al. · 2011AnimalPharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats — [animal PK]View study →}. Oral bioavailability is moderate (~35% in rat) with an intravenous half-life near 1.8 hours; the major circulating species is pterostilbene-4′-sulfate, but tissue exposure runs 2- to 25-fold above blood, and — importantly for the neuro claims — intact (unconjugated) pterostilbene predominates in the brain ^{8Reference 8Azzolini et al. · 2014AnimalPharmacokinetics and tissue distribution of pterostilbene in the rat — [animal PK]View study →}. Human pharmacokinetic characterization is limited and much of the quantitative data is rodent ^{9Reference 9Wang et al. · 2018ReviewMetabolism and pharmacokinetics of resveratrol and pterostilbene — [review]View study →}; newer cocrystal formulations are being trialled specifically to raise human exposure.

Clinical trials

Registered human activity is modest and dominated by the nicotinamide-riboside combination product (Basis/NRPT/EH301) rather than pterostilbene alone; standalone pterostilbene trials are mostly small safety, bioavailability, or single-outcome studies. The most striking of the combination results is an ALS pilot in which 32 patients on EH301 for four months showed slower functional decline, better pulmonary function and greater muscle strength than placebo — but it is a single-center pilot, co-authored by the manufacturer, and it tested the combination rather than pterostilbene ^{6Reference 6de la Rubia et al. · 2019RCTEfficacy and tolerability of EH301 for amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled pilot study — [RCT, pilot]View study →}. As an off-patent natural compound, it attracts little large-scale industry efficacy investment.

Last checked: July 2026.

Dietary Sources

Pterostilbene is a phytoalexin — a compound plants make under stress — and dietary amounts are small. Blueberries are the best-known food source, with grapes, some other berries, and peanuts contributing lesser amounts; the compound is also present in the heartwood of Pterocarpus marsupium (Indian kino), the traditional-medicine source from which it was first characterized.

Food source	Relative pterostilbene content	Notes
Blueberries	Highest common dietary source	Content varies widely by cultivar, ripeness and growing conditions
Grapes / grape products	Low–moderate	Alongside resveratrol; concentrated in skin
Peanuts	Low	Present but minor
Pterocarpus marsupium heartwood	High (non-food botanical)	Historical/traditional source, used in some extracts

The practical point: even blueberry-rich diets deliver on the order of a few milligrams at most, whereas studied supplemental doses are 50–250 mg — so the food supply is nowhere near the amounts tested in trials. Supplemental pterostilbene is manufactured (synthesized or produced biotechnologically) for this reason ^{12,13Reference 12Nagarajan et al. · 2022ReviewNew insights into dietary pterostilbene: sources, metabolism, and health promotion effects — [review]View study →Reference 13Lin et al. · 2020ReviewOccurrence, bioavailability, anti-inflammatory, and anticancer effects of pterostilbene — [review]View study →}.

Dosage & Intake

Pterostilbene is not an essential nutrient, so there is no RDA/AI and no official Tolerable Upper Intake Level. Human trials have used 50–250 mg/day, typically split as twice-daily dosing. The blood-pressure effect appeared at the top of that range (125 mg twice daily = 250 mg/day) ^{1Reference 1Riche et al. · 2014RCTAnalysis of pterostilbene on metabolic parameters: a randomized, double-blind, and placebo-controlled trial — [RCT]View study →}, while the same monotherapy dose is where the LDL-cholesterol rise was seen ^{1Reference 1Riche et al. · 2014RCTAnalysis of pterostilbene on metabolic parameters: a randomized, double-blind, and placebo-controlled trial — [RCT]View study →}. In the nicotinamide-riboside combination products, the pterostilbene component is often lower (~100–200 mg/day) ^{3,4Reference 3Dellinger et al. · 2023RCTNicotinamide riboside and pterostilbene reduces markers of hepatic inflammation in NAFLD: a double-blind, placebo-controlled clinical trial — [RCT]View study →Reference 4Jensen et al. · 2022RCTA randomized placebo-controlled trial of nicotinamide riboside and pterostilbene supplementation in experimental muscle injury in elderly individuals — [RCT, null]View study →}. Because pterostilbene is lipophilic, taking it with a fat-containing meal is reasonable, though dedicated food-effect data in humans are limited.

These are doses studied in research, not a personal recommendation.

Safety

Pterostilbene has been well tolerated across the human trials so far, with one consistent exception — monotherapy raised LDL cholesterol, which is the single finding anyone managing lipids needs to know about.

Safety at a Glance

✅ Low / no toxicityCardiac risk

• Well tolerated to 250 mg/day. No adverse effects on liver, kidney or glucose markers over 6–8 weeks, and lower toxicity than resveratrol.
• Monotherapy raised LDL cholesterol by about 17 mg/dL. Anyone with hyperlipidemia or on lipid management should factor this in and monitor.
• Not assessed in pregnancy or breastfeeding. No human safety data beyond food amounts — see the box below.
• Interaction data are sparse. Additive effects with antidiabetic and antihypertensive drugs are plausible but not formally characterized.
• No official Upper Limit. 250 mg/day is a trial dose, not a safety ceiling, and long-term high-dose data are lacking.

Full Safety & Interactions Detail

Across the human trials to date, pterostilbene has been well tolerated: the dedicated safety analysis of the 80-person metabolic trial found no adverse effects on liver, kidney, or glucose markers and no significant self-reported adverse reactions at up to 250 mg/day over 6–8 weeks ^{2Reference 2Riche et al. · 2013RCTAnalysis of safety from a human clinical trial with pterostilbene — [RCT, safety]View study →}, and the NRPT trials reported good tolerability ^{3,4,5Reference 3Dellinger et al. · 2023RCTNicotinamide riboside and pterostilbene reduces markers of hepatic inflammation in NAFLD: a double-blind, placebo-controlled clinical trial — [RCT]View study →Reference 4Jensen et al. · 2022RCTA randomized placebo-controlled trial of nicotinamide riboside and pterostilbene supplementation in experimental muscle injury in elderly individuals — [RCT, null]View study →Reference 5Simic et al. · 2020RCTNicotinamide riboside with pterostilbene (NRPT) increases NAD⁺ in patients with acute kidney injury — [RCT, safety]View study →}. Reviews consistently note lower toxicity than resveratrol ^{13Reference 13Lin et al. · 2020ReviewOccurrence, bioavailability, anti-inflammatory, and anticancer effects of pterostilbene — [review]View study →}.

The one consistent red flag is lipids: pterostilbene monotherapy raised LDL cholesterol by about 17 mg/dL, an effect that was attenuated when it was combined with grape extract or when the person was already on a cholesterol medication ^{1Reference 1Riche et al. · 2014RCTAnalysis of pterostilbene on metabolic parameters: a randomized, double-blind, and placebo-controlled trial — [RCT]View study →}.

Anyone with hyperlipidemia or on lipid management should factor this in and monitor. Interaction data are sparse; given AMPK/glucose effects and blood-pressure lowering, theoretical additive effects with antidiabetic and antihypertensive drugs are plausible but not formally characterized.

Scope of this safety review (for honesty, not a claim):

• Interactions assessed? Partially — theoretical additive effects with antihypertensive and antidiabetic drugs are noted, but no formal human drug-interaction studies were identified.
• Pregnancy/lactation assessed? No — no human data; treated as “avoid, not assessed.”
• Upper Limit? No official UL exists; well-tolerated to 250 mg/day in short trials, but that is not a safety ceiling and long-term high-dose data are lacking.

Pregnancy & Lactation

• Caution in pregnancy• Caution while breastfeeding

Verdict: avoid — not assessed. There are no human pregnancy or lactation safety data for supplemental pterostilbene. Pregnant or breastfeeding people should not take it beyond amounts naturally present in food.

References

1. Riche, D. M., et al. (2014). Analysis of pterostilbene on metabolic parameters: a randomized, double-blind, and placebo-controlled trial — [RCT]. Evidence-Based Complementary and Alternative Medicine. https://pubmed.ncbi.nlm.nih.gov/25057276/
2. Riche, D. M., et al. (2013). Analysis of safety from a human clinical trial with pterostilbene — [RCT, safety]. Journal of Toxicology. https://pubmed.ncbi.nlm.nih.gov/23431291/
3. Dellinger, R. W., et al. (2023). Nicotinamide riboside and pterostilbene reduces markers of hepatic inflammation in NAFLD: a double-blind, placebo-controlled clinical trial — [RCT]. Hepatology. https://pubmed.ncbi.nlm.nih.gov/36082508/
4. Jensen, J. B., et al. (2022). A randomized placebo-controlled trial of nicotinamide riboside and pterostilbene supplementation in experimental muscle injury in elderly individuals — [RCT, null]. JCI Insight. https://pubmed.ncbi.nlm.nih.gov/35998039/
5. Simic, P., et al. (2020). Nicotinamide riboside with pterostilbene (NRPT) increases NAD⁺ in patients with acute kidney injury — [RCT, safety]. BMC Nephrology. https://pubmed.ncbi.nlm.nih.gov/32791973/
6. de la Rubia, J. E., et al. (2019). Efficacy and tolerability of EH301 for amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled pilot study — [RCT, pilot]. Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. https://pubmed.ncbi.nlm.nih.gov/30668199/
7. Kapetanovic, I. M., et al. (2011). Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats — [animal PK]. Cancer Chemotherapy and Pharmacology. https://pubmed.ncbi.nlm.nih.gov/21116625/
8. Azzolini, M., et al. (2014). Pharmacokinetics and tissue distribution of pterostilbene in the rat — [animal PK]. Molecular Nutrition & Food Research. https://pubmed.ncbi.nlm.nih.gov/25047917/
9. Wang, P., & Sang, S. (2018). Metabolism and pharmacokinetics of resveratrol and pterostilbene — [review]. BioFactors. https://pubmed.ncbi.nlm.nih.gov/29315886/
10. Pari, L., & Satheesh, M. A. (2006). Effect of pterostilbene on hepatic key enzymes of glucose metabolism in streptozotocin- and nicotinamide-induced diabetic rats — [animal]. Life Sciences. https://pubmed.ncbi.nlm.nih.gov/16616938/
11. Ren, B. C., et al. (2018). AMPK activation by pterostilbene contributes to suppression of hepatic gluconeogenic gene expression and glucose production — [in vitro]. Biochemical and Biophysical Research Communications. https://pubmed.ncbi.nlm.nih.gov/29524400/
12. Nagarajan, S., et al. (2022). New insights into dietary pterostilbene: sources, metabolism, and health promotion effects — [review]. Molecules. https://pubmed.ncbi.nlm.nih.gov/36234852/
13. Lin, W. S., et al. (2020). Occurrence, bioavailability, anti-inflammatory, and anticancer effects of pterostilbene — [review]. Journal of Agricultural and Food Chemistry. https://pubmed.ncbi.nlm.nih.gov/32064876/
14. Kim, H., et al. (2020). Chemistry of pterostilbene and its metabolic effects — [review]. Journal of Agricultural and Food Chemistry. https://pubmed.ncbi.nlm.nih.gov/32125846/
15. La Spina, M., et al. (2019). Pterostilbene improves cognitive performance in aged rats: an in vivo study — [animal]. Cellular Physiology and Biochemistry. https://pubmed.ncbi.nlm.nih.gov/30816671/
16. Meng, J., et al. (2019). Pterostilbene attenuates amyloid-β-induced neurotoxicity by regulating the PDE4A-CREB-BDNF pathway — [animal]. American Journal of Translational Research. https://pubmed.ncbi.nlm.nih.gov/31737188/
17. Hemani, S., et al. (2022). Dietary pterostilbene for MTA1-targeted interception in high-risk premalignant prostate cancer — [animal]. Cancer Prevention Research. https://pubmed.ncbi.nlm.nih.gov/34675064/

View all 17 references▾